Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 1998

View Archived Issues

Company Profile: Telik

Xoma completes phase II enrollment in psoriasis study

Kosan enters research collaboration with J&J

Rhone-Poulenc Rorer's Estalis approved in 12 E.U. countries

Inex demonstrates effectiveness of new antisense drug

Perprazole filings to be made within a year

Diatide brings first Techtide product to market

Neutrophil inhibitor peptides available for licensing from RCT

Scientists report significant finding related to the genetics of insulin-dependent diabetes

Nicotinic acetylcholine receptor ligands from Pfizer for addictive and CNS disorders

Ono's new PGE2 derivatives show binding affinity for EP2 receptors

Trega concludes phase I testing of HP-228 inhalation formulation

Antiatherosclerotic compounds prepared by Bayer scientists

Lundbeck develops new antipsychotic agents acting on D1 receptors

Novel central 5-HT1A receptor agonists characterized in binding and animal studies

Erythromycin derivatives for Gram-positive infections disclosed by Hoechst Marion Roussel

Antiatherogenic activity of antioxidant BO-653 explored in animal models

Demegen's Peptidyl MIM compound D4B effectively treats infected wounds

Gene therapy targeting Tie2 receptor tyrosine kinase evaluated as antiangiogenic strategy

Promising preclinical findings reported for PI-88; phase I testing begins next month

5-HT2C agonist shows potential for treating OCD and depression

NCIC-CTG leads major international trial for new ovarian cancer compound

Matrix reports promising phase III results for IntraDose in breast cancer

LXR redirects resources to three strategic development programs

GeneMedicine receives NIH grant to pursue AAT Gene Medicine

Pharmos successfully completes phase II head trauma study

Oralin cleared for phase III trials in Ecuador; regulatory clearance expected by year-end

DepoTech and Chiron submit NDA for DepoCyt

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...